For patients living with autoimmune kidney disease, the difference between preserving kidney function and progressing to dialysis often hinges on which immunotherapy gets used — and when. A major international consensus exercise has now produced the most comprehensive comparative map to date of B-cell-targeted treatments across the principal immune-mediated glomerular diseases, revealing that efficacy is far from uniform and that next-generation agents are beginning to outperform the rituximab-era standard.
The Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, convened in Panama City in June 2025, synthesized evidence across IgA nephropathy, membranous nephropathy, steroid-dependent nephrotic syndrome, lupus nephritis, and antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. The findings expose a striking disease-specificity paradox: anti-CD20 therapy (rituximab) is first-line in membranous nephropathy — achieving at least partial remission in most patients by 18 months — yet shows limited efficacy in IgA nephropathy, where agents blocking the B-cell survival factors BAFF and APRIL, or anti-CD38 antibodies, more meaningfully reduce proteinuria and slow glomerular filtration rate decline. In lupus nephritis, the anti-CD20 antibody obinutuzumab and CAR T-cell therapy have emerged as high-signal contenders, with CAR T cells suggesting the possibility of sustained drug-free remission — a genuinely novel therapeutic horizon for an otherwise relapsing disease.
This consensus matters beyond nephrology. It illustrates how a single mechanistic class — B-cell depletion — can behave as a precision tool in one condition and a blunt instrument in another, depending on the underlying immunopathology. The BAFF/APRIL axis finding in IgA nephropathy aligns with mucosal immune dysregulation hypotheses and is consistent with early-phase trial data for atacicept and telitacicept that have been accumulating since 2022. The CAR T-cell signal in lupus nephritis is the most paradigm-challenging element: if durable remissions are confirmed in larger controlled trials, it could redefine treatment ambition from disease suppression to potential immune reset. Key limitations include the conference's synthesis format — this is expert consensus informed by heterogeneous trial data, not a new meta-analysis — and global access disparities that make newer agents theoretical options for most patients worldwide.